Biogen's tau drug reports mixed Alzheimer's results, as low dose performs better

AAIC in London (Ryan Cross/Endpoints News) July 14, 2026 09:15 AM EDT R&D Ques­tions linger over Bio­gen's tau drug for Alzheimer's, as low dose re­ports bet­ter re­sults Ryan Cross Senior Science Correspondent LON­DON — Bio­gen’s at­tempt to treat Alzheimer’s by go­ing af­ter a pro­tein that forms tox­ic tan­gles in the brain showed some of the strongest proof yet … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER